AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

 AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

Shots:

  • The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees
  • AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical immunomics database of 58B+ immune cell receptors and antigens
  • AstraZeneca gets an option to enter into an agreement with Adaptive for the development & commercialization of a CDx or therapeutic application based on T-MAP data. ImmunoSEQ T-MAP combines the sequencing and mapping capabilities of Adaptive to map TCRs to antigens, across AZ’s oncology portfolio

Click here ­to­ read full press release/ article | Ref: Adaptive | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post